Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ENTA

ENTA - Enanta Pharmaceuticals Inc Stock Price, Fair Value and News

$12.65-0.33 (-2.54%)
Market Closed

14/100

ENTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

ENTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$10.42

Target 3M

$11.72

Target 6M

$11.07

ENTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENTA Price Action

Last 7 days

0.6%

Last 30 days

-23.0%

Last 90 days

16.5%

Trailing 12 Months

147.1%

ENTA RSI Chart

ENTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENTA Valuation

Market Cap

365.1M

Price/Earnings (Trailing)

-4.46

Price/Sales (Trailing)

5.59

EV/EBITDA

-4.74

Price/Free Cashflow

-11.35

ENTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$10.42

Target 3M

$11.72

Target 6M

$11.07

ENTA Fundamentals

ENTA Revenue

Revenue (TTM)

65.3M

Rev. Growth (Yr)

3.55%

Rev. Growth (Qtr)

-17.41%

ENTA Earnings

Earnings (TTM)

-81.9M

Earnings Growth (Yr)

35.12%

Earnings Growth (Qtr)

-2.44%

ENTA Profitability

EBT Margin

-127.90%

Return on Equity

-126.53%

Return on Assets

-29.17%

Free Cashflow Yield

-8.81%

ENTA Investor Care

Shares Dilution (1Y)

36.18%

Diluted EPS (TTM)

-3.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202564.5M64.8M65.3M0
202472.9M72.0M67.6M66.6M
202381.2M80.6M79.2M73.6M
202291.6M89.4M86.2M82.1M
202194.2M97.1M97.1M93.0M
2020175.9M150.2M122.5M101.6M
2019234.0M221.1M205.2M187.9M
2018165.6M215.3M206.6M238.4M
201746.2M39.7M102.8M130.5M
201687.5M89.8M88.3M50.2M
2015179.6M149.1M160.9M131.8M
20146.1M46.5M47.7M124.3M
201336.9M34.5M32.1M5.1M
20120041.7M39.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Enanta Pharmaceuticals Inc

ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEenanta.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES160

Enanta Pharmaceuticals Inc Frequently Asked Questions

ENTA is the stock ticker symbol of Enanta Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Enanta Pharmaceuticals Inc is 365.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ENTA's fair value in chart for subscribers.

The fair value guage provides a quick view whether ENTA is over valued or under valued. Whether Enanta Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Enanta Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENTA.

As of Wed Jan 28 2026, ENTA's PE ratio (Price to Earnings) is -4.46 and Price to Sales (PS) ratio is 5.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENTA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Enanta Pharmaceuticals Inc has provided -0.068 (multiply by 100 for percentage) rate of return.